Silexion Therapeutics Corp SLXN
0.26
0.00
0.00%
as of 25 Sep
- Market cap
- $1.4M
- P/E
- 0.0×
Follow SLXN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
3.97 | 2.41 | 1.00 | 0.94 |
Net Debt/EBITDA |
2.35 | 1.01 | 0.89 | 0.61 | |
Debt/Assets |
13.26% | 21.73% | 0.00% | 0.00% | |
Debt/Equity |
0.22 | 0.60 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.87 | 0.68 | 1.33 | 0.82 | |
Capex/Depreciation |
0.00 | (0.67) | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(25.09) | (22.69) | (11.29) | (4.26) | |
Cash per Share |
81.81 | 45.25 | 7.55 | 3.29 | |
Shareholders Equity per Share |
61.58 | 19.57 | 0.90 | 0.06 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
61.58 | 19.57 | 0.90 | 0.06 | |
Free Cash Flow |
(2.84) | (3.02) | (3.65) | (2.92) | |
Working Capital |
8.27 | 3.88 | 0.01 | (0.23) | |
Capital Expenditures |
0.00 | 0.00 | — | — | |
Net Current Asset Value |
6.42 | 2.03 | (0.25) | (0.46) | |
| Other line items | |||||
Quick Ratio |
3.33 | 2.18 | 0.60 | 0.57 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(25.09) | (22.68) | (11.29) | (4.26) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Average Payables |
0.87 | 0.86 | 0.82 | 0.94 | |
Average Assets |
7.35 | 5.04 | 6.46 | 5.02 | |
Average Common Equity |
1.20 | (0.69) | 1.44 | 0.08 | |
Capex to Sales |
0.00 | 0.00 | — | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates